Transformation of a Dopamine D2 Receptor Agonist to Partial Agonists as Novel Antipsychotic Agents

被引:2
|
作者
Liu, Ruiquan [1 ]
Qi, Jianzhong [2 ,3 ]
Wang, Huan [1 ]
Fan, Luyu [2 ,3 ]
Zhang, Pei [2 ,3 ]
Yu, Jing [2 ,3 ]
Tan, Liang [1 ]
Wang, Sheng [2 ,3 ]
Cheng, Jianjun [1 ,4 ]
机构
[1] ShanghaiTech Univ, iHuman Inst, Shanghai 201210, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Ctr Excellence Mol Cell Sci, State Key Lab Mol Biol, Shanghai 200031, Peoples R China
[3] Univ Chinese Acad Sci, Shanghai 200031, Peoples R China
[4] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China
基金
中国国家自然科学基金;
关键词
DISCOVERY; DESIGN;
D O I
10.1021/acs.jmedchem.3c00098
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Designed ligands of G protein-coupled receptors can exert a spectrum of modulating effects, varying from full agonists and partial agonists to antagonists and inverse agonists. For the dopamine D2 receptor (D2R), partial agonist activity is the pharmacological feature of the third-generation antipsychotics, including aripiprazole, brexpiprazole, and cariprazine. Started from a benzofuran-derived D2R full agonist O4LE6 (4), which was identified using a structure-based method by us in previous studies, a series of D2R partial agonists were designed and synthesized by introducing different tail groups. Among them, compound 10b showed excellent activity in D2R pharmacological assays. Further optimizations using a structural rigidification approach led to the discovery of brain-penetrant compounds 29c and 29d, which exhibited potent antipsychotic effects in the mouse hyperlocomotion model. Compound 29c also showed excellent drug-like pharmacokinetic properties in rats and qualifies as an antipsychotic agent that is worth further evaluations.
引用
收藏
页码:6274 / 6287
页数:14
相关论文
共 50 条
  • [1] Pharmacology of aripiprazole, a novel antipsychotic:: dopamine D2 receptor partial agonist
    Kikuchi, T
    Arlene, S
    Yocca, F
    Tadori, Y
    Hirose, T
    McQuade, R
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2004, 19 (03) : 190 - 190
  • [2] Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic
    Keck, PE
    McElroy, SL
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (04) : 655 - 662
  • [3] Aripiprazole, a novel antipsychotic, is a potent partial agonist at human dopamine D2 receptors
    Burris, KD
    Molski, TF
    Ryan, E
    Xu, C
    Tottori, K
    Kikuchi, T
    Yocca, FD
    Molinoff, PB
    [J]. SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 88 - 88
  • [4] Serotonergic agonists behave as partial agonists at the dopamine D2 receptor
    Rinken, A
    Ferré, S
    Terasmaa, A
    Owman, C
    Fuxe, K
    [J]. NEUROREPORT, 1999, 10 (03) : 493 - 495
  • [5] Neurochemical and behavioural actions of a novel dopamine D3/D2 receptor antagonist/partial agonist putative antipsychotic
    Kiss, B.
    Gyertyan, I.
    Saghy, K.
    Laszlovszky, I
    Horvath, A.
    Laszy, J.
    Schmidt, E.
    Szabo, Gy
    Againe, Csongor E.
    Adham, N.
    Tihanyi, K.
    Szombathelyi, Zs
    [J]. ACTA PHARMACOLOGICA SINICA, 2006, 27 (09) : 1274 - 1275
  • [6] Novel dopamine D2 partial agonists in the treatment of schizophrenia
    Correll, C.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S668 - S668
  • [7] Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors
    Burris, KD
    Molski, TF
    Xu, C
    Ryan, E
    Tottori, K
    Kikuchi, T
    Yocca, FD
    Molinoff, PB
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (01): : 381 - 389
  • [8] Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
    Jin Mizushima
    Keisuke Takahata
    Noriko Kawashima
    Motoichiro Kato
    [J]. Annals of General Psychiatry, 11
  • [9] Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
    Mizushima, Jin
    Takahata, Keisuke
    Kawashima, Noriko
    Kato, Motoichiro
    [J]. ANNALS OF GENERAL PSYCHIATRY, 2012, 11
  • [10] From antipsychotic to D2 antagonists and D2 partial agonists
    Stahl, S.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S152 - S152